» Articles » PMID: 20224859

Prognostic Value of Histological and Immunohistochemical Characteristics for Predicting the Recurrence of Medullary Thyroid Carcinoma

Overview
Journal Ann Surg Oncol
Publisher Springer
Specialty Oncology
Date 2010 Mar 13
PMID 20224859
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: In medullary thyroid carcinoma, there is currently no consensus about the prognostic value of histological and immunohistochemical parameters. This study was designed to analyze the value of various histological and immunohistochemical characteristics for predicting the recurrence of medullary carcinoma.

Methods: A total of 55 cases of medullary thyroid carcinoma have been reviewed. These were operated on consecutively between 1971 and 2004 after histological confirmation. The data referring to clinical characteristics and evolution were taken from the patient's clinical history. The macroscopic, microscopic, and immunohistochemical characteristics of the tumors were taken from the pathological anatomy report.

Results: In 14 (27%) cases, there was recurrence of the disease. The disease-free interval at 1 year was 88 +/- 5%; at 5 years 73 +/- 7%; at 10 years 73 +/- 7%; at 15 years 61 +/- 10%; and at 20 years or more 61 +/- 10%. Of the histological parameters, only vascular invasion (0.0098) was related to a higher relapse rate. No epidemiological variable or immunohistochemical marker was associated with relapse. However, it was found that staging (P = 0.0102), as well as tumor size (P = 0.0211) and lymph node affectation (P = 0.0012), are factors significantly related to relapse of the disease. According to Cox's regression model, the only variable with a statistically significant effect was vascular invasion (P = 0.0056; odds ratio = 5.2308).

Conclusions: The overall recurrence rate was 27%, and the main independent prognostic factor of recurrence was tumoral vascular invasion at diagnosis. Staging, tumor size, and lymph node metastasis are prognostic factors of recurrence, although they are not significant in the multivariate analysis.

Citing Articles

Sex differences and racial/ethnic disparities in the presentation and treatment of medullary thyroid cancer.

Kalva S, Ginzberg S, Passman J, Soegaard Ballester J, Finn C, Fraker D Am J Surg. 2024; 234:19-25.

PMID: 38365554 PMC: 11223966. DOI: 10.1016/j.amjsurg.2024.02.009.


Management of Medullary Thyroid Cancer: Patterns of Recurrence and Outcomes of Reoperative Surgery.

Papachristos A, Nicholls L, Mechera R, Aniss A, Robinson B, Clifton-Bligh R Oncologist. 2023; 28(12):1064-1071.

PMID: 37632760 PMC: 10712713. DOI: 10.1093/oncolo/oyad232.


Independent Validation of the International Grading System for Medullary Thyroid Carcinoma: A Single Institution Experience.

Lubin D, Behrman D, Goyal S, Magliocca K, Shi Q, Chen A Mod Pathol. 2023; 36(9):100235.

PMID: 37270155 PMC: 10528047. DOI: 10.1016/j.modpat.2023.100235.


Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma.

Jung C, Agarwal S, Hang J, Lim D, Bychkov A, Mete O Endocr Pathol. 2023; 34(1):1-22.

PMID: 36890425 DOI: 10.1007/s12022-023-09753-5.


Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies.

Czajkowski M, Kaemmerer D, Sanger J, Sauter G, Wirtz R, Schulz S BMC Cancer. 2022; 22(1):740.

PMID: 35799158 PMC: 9261050. DOI: 10.1186/s12885-022-09839-z.